Is Orlistat Better Than Mounjaro for Weight Loss?

The mechanism gap: why these two medicines feel so different

Orlistat is a lipase inhibitor. It sits in the gut and prevents the enzyme that breaks down fat from doing its job, so roughly a third of the fat you eat passes through undigested rather than being stored. That sounds elegant, but the catch is immediate: if you eat a high-fat meal, the unabsorbed fat has to go somewhere. Many people manage this by lowering dietary fat deliberately, and some find that a useful nudge towards better food choices. Others find the side effects (loose, oily stools and an urgent need for the bathroom) very difficult to live with long-term.

Mounjaro (tirzepatide) does something fundamentally different. It activates both the GIP and GLP-1 receptors involved in appetite regulation and blood-sugar signalling, reducing how hungry you feel and slowing the speed at which the stomach empties. The result is that many people eat less simply because food becomes less preoccupying, not because they are fighting willpower. The full Mounjaro overview covers the mechanism in more detail if you want the deeper picture. Both are prescription-only medicines requiring clinical assessment before you can access them legally in the UK.

A common misconception is that orlistat is a safer choice simply because it has been around longer. Familiarity does not equal superior safety or superior results; the two medicines have different risk profiles, different tolerability patterns and very different average outcomes in the evidence base, and our detailed comparison of orlistat and Mounjaro sets out those differences side by side if you want a closer look.

What the evidence actually shows

The clinical trial data puts meaningful distance between these two medicines on average weight loss. In SURMOUNT-1, tirzepatide at its highest dose produced an average body-weight reduction of around 20 to 21 percent over 72 weeks, figures cited directly in NICE's appraisal of tirzepatide (TA1026). For context, NICE notes that if patients do not achieve at least five percent weight loss after six months at the highest tolerated dose, continuing treatment is reviewed.

Orlistat trials have historically shown more modest averages. A systematic review of orlistat versus placebo found mean weight loss of roughly three to five kilograms more than placebo over twelve months, significant for some patients, but considerably lower than tirzepatide in head-to-head terms. Orlistat has no equivalent phased NICE technology appraisal for weight management; its use is guided by clinical judgement and the NHS orlistat patient information.

The table below summarises the key factual differences.

Who each medicine tends to suit, and where the decision lands

Orlistat can be a reasonable starting point for people with a lower BMI, those who cannot tolerate injections, or those who want an over-the-counter or lower-cost option and are already committed to reducing dietary fat. It works best when it accompanies genuine changes to eating habits, and some prescribers use the side effects deliberately as a behaviour-reinforcing tool, not elegant, but occasionally effective in the right person.

Mounjaro is licensed for adults with a BMI of 30 or above, or 27 or above with a weight-related condition such as high blood pressure, type 2 diabetes or dyslipidaemia. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. Its hormone-pathway approach tends to suit people for whom appetite and satiety have been the central obstacle, and the trial evidence shows considerably greater average outcomes. Our patient experience page carries more context on how people describe the treatment in practice.

Some people start on orlistat and later want to explore whether an injectable option is appropriate, there is a dedicated guide on switching from orlistat to Mounjaro that covers what a clinical review at that point typically considers. There are also broader comparisons of GLP-1 medicines for those considering more than one option, and a look at whether any current alternative outperforms Mounjaro in the existing evidence.

Accessing whichever treatment is right for you

Neither of these medicines is available without a prescription from a registered prescriber who has assessed your health picture. That assessment matters practically, not just legally: orlistat interacts with certain fat-soluble vitamins and some anticoagulants; Mounjaro requires specific counselling around contraception for women using oral pills (absorption of the pill can be reduced, and an additional non-oral method is advised for the first four weeks and after each dose increase). The NHS tirzepatide patient information covers the full list of considerations.

At nume, a prescriber reviews your consultation the same day, not an algorithm. If Mounjaro is clinically suitable, treatment reaches you the next working day. If you are curious about the clinical team making those decisions, our lead prescriber's profile sets out the approach. For questions before you start, the FAQs page covers the most common ones. Which medicine suits you is a clinical decision made with our prescribers, not a verdict handed down by a comparison table.